Ifp Advisors, Inc Supernus Pharmaceuticals, Inc. Transaction History

Ifp Advisors, Inc

$3.28 Billion
Q2 2025

A detailed history of Ifp Advisors, Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 106 shares of SUPN stock, worth $6,042. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106

Previous 6 1666.67%

Holding current value

$6,042

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 24, 2025	BUY	$30.29 - $33.43 $3,029 - $3,343	100 Added 1666.67%	106 $3,000
Q4 2024 Feb 04, 2025	BUY	$31.89 - $37.83 $191 - $226	6 New	6 $0
Q4 2023 Jan 09, 2024	BUY	$22.72 - $29.68 $1,499 - $1,958	66 Added 100.0%	132 $3,000
Q1 2023 Apr 18, 2023	SELL	$34.93 - $42.03 $95,812 - $115,288	-2,743 Reduced 97.65%	66 $2,000
Q4 2022 Feb 07, 2023	SELL	$31.09 - $37.88 $3,544 - $4,318	-114 Reduced 3.9%	2,809 $157,000
Q3 2022 Nov 08, 2022	BUY	$28.79 - $35.41 $12,667 - $15,580	440 Added 17.72%	2,923 $164,000
Q2 2022 Sep 06, 2022	BUY	$25.33 - $34.25 $62,894 - $85,042	2,483 New	2,483 $140,000
Q2 2022 Aug 12, 2022	SELL	$25.33 - $34.25 $62,894 - $85,042	-2,483 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$28.51 - $32.9 $44,019 - $50,797	1,544 Added 164.43%	2,483 $80,000
Q1 2022 Aug 08, 2022	BUY	$28.51 - $32.9 $456 - $526	16 Added 1.73%	939 $30,000
Q4 2021 Jan 12, 2022	SELL	$26.37 - $34.22 $606 - $787	-23 Reduced 2.43%	923 $29,000
Q3 2021 Oct 06, 2021	BUY	$23.54 - $31.39 $17,937 - $23,919	762 Added 414.13%	946 $28,000
Q2 2021 Jul 13, 2021	BUY	$26.72 - $33.19 $3,152 - $3,916	118 Added 178.79%	184 $6,000
Q1 2021 Apr 30, 2021	BUY	$24.15 - $31.45 $1,593 - $2,075	66 New	66 $2,000
Q4 2020 Jan 25, 2021	BUY	$17.7 - $25.81 $0 - $0	0 New	0 $0
Q3 2020 Oct 29, 2020	BUY	$20.2 - $25.05 $0 - $0	0 New	0 $0
Q2 2020 Aug 05, 2020	BUY	$17.09 - $24.89 $0 - $0	0 New	0 $0
Q1 2020 May 12, 2020	BUY	$14.45 - $24.69 $0 - $0	0 New	0 $0
Q4 2019 Jan 17, 2020	BUY	$19.93 - $29.13 $0 - $0	0 New	0 $0
Q3 2019 Nov 07, 2019	BUY	$25.47 - $33.37 $0 - $0	0 New	0 $0
Q1 2019 May 15, 2019	SELL	$32.77 - $41.99 $57,642 - $73,860	-1,759 Closed	0 $0
Q4 2018 Jan 23, 2019	BUY	$30.84 - $49.51 $647 - $1,039	21 Added 1.21%	1,759 $58,000
Q3 2018 Oct 25, 2018	SELL	$42.7 - $56.55 $33,519 - $44,391	-785 Reduced 31.11%	1,738 $0
Q2 2018 Aug 07, 2018	BUY	$44.1 - $59.85 $19,271 - $26,154	437 Added 20.95%	2,523 $0
Q1 2018 Jun 03, 2019	BUY	$37.15 - $46.9 $2,154 - $2,720	58 Added 2.86%	2,086 $83,000
Q1 2018 May 09, 2018	SELL	$37.15 - $46.9 $2,154 - $2,720	-58 Reduced 2.78%	2,028 $0
Q4 2017 Jan 24, 2018	SELL	$36.4 - $42.6 $33,670 - $39,405	-925 Reduced 30.72%	2,086 $0
Q3 2017 Oct 30, 2017	BUY	$36.75 - $49.65 $18,632 - $25,172	507 Added 20.25%	3,011 $120,000
Q2 2017 Jun 03, 2019	SELL	N/A	-43 Reduced 1.69%	2,504 $108,000
Q1 2017 Jun 03, 2019	BUY	N/A	242 Added 10.5%	2,547 $80,000
Q4 2016 Jun 03, 2019	SELL	N/A	-108 Reduced 4.48%	2,305 $58,000
Q2 2016 Jun 03, 2019	BUY	N/A	2,413	2,413 $49,000

Others Institutions Holding SUPN

# of Institutions

321

Shares Held

61M

Call Options Held

18.4K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $3.05B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account